GlassScriptPhysician profile
Mark Stanton Robbins
NPI 1265442206
$6,500.10
in general payments reported to CMS, 2019-2025
60 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $990 · 2021: $1,004 · 2022: $1,067 · 2023: $1,925 · 2024: $65.13 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.25 |
| Education | $106.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $554.42 | 2019-2023 | Opdivo, Opdualag |
| Amgen INC. | $481.17 | 2019-2023 | Lumakras |
| Lilly USA, LLC | $455.07 | 2019-2023 | Verzenio, Jaypirca |
| Merck Sharp & Dohme LLC | $421.56 | 2019-2023 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $397.43 | 2019-2023 | Kisqali, Piqray |
| Janssen Biotech, INC. | $336.35 | 2019-2023 | Darzalex, Imbruvica |
| Eisai INC. | $324.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $276.40 | 2019-2023 | Tagrisso, Imfinzi |
| Celgene Corporation | $195.19 | 2019-2023 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $188.55 | 2019-2023 | Enhertu |
| Stryker Corporation | $182.76 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Incyte Corporation | $181.74 | 2019-2023 | Jakafi, Monjuvi |
| Genzyme Corporation | $166.83 | 2019-2023 | |
| Seagen INC. | $159.46 | 2020-2023 | Tukysa, Padcev, Adcetris |
| Genentech USA, INC. | $148.42 | 2019-2023 | Phesgo, Kadcyla, Perjeta |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.